PTK2 and skin squamous cell carcinoma: Additionally, when FAK inhibitors were combined with agents that induce T-cell costimulatory pathways in skin squamous cell carcinoma, the tumors became more sensitive to FAK inhibitors, and this effect was mediated by CD80.